Assembly Biosciences Inc. (ASMB)
ASMB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$20.34
-10.67% on the day
Market cap
$414.1M
Small cap
Revenue · 2025
$72.3M
+153.5% on 2024
Net income · 2025
-$6.1M
-8.5% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ASMB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2010 |
| SEC CIK | 0001426800 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $72.3M |
| Net income | -$6.1M |
| Operating income | -$12.1M |
| Net margin | -8.5% |
| Operating margin | -16.8% |
| Revenue growth | +153.5% |
| Cash | $58.5M |
| Total assets | $257.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 5.7× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-26 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K/A | 2026-08-14 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 893 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -11.1% |
| 1 month | -21.8% |
| 3 months | -21.0% |
| Year to date | -40.0% |
| 1 year | -26.2% |
| From 52-week high | -47.0% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DMAC | DiaMedica Therapeutics Inc. | $7.82 | -4.63% | $421.7M |
| SPRY | ARS Pharmaceuticals Inc. | $4.05 | -3.11% | $402.8M |
| OVID | Ovid Therapeutics Inc. | $2.19 | -9.13% | $427.7M |
| CAPR | Capricor Therapeutics Inc. | $6.88 | -7.90% | $400.0M |
| PRTA | Prothena Corporation plc | $8.36 | -0.83% | $429.2M |
| AVIR | Atea Pharmaceuticals Inc. | $4.98 | -0.99% | $399.4M |
| NGNE | Neurogene Inc. Common Stock | $21.56 | -11.78% | $431.4M |
| KMDA | Kamada Ltd. | $7.69 | -1.91% | $443.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier